Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

NCT03629925 PHASE3 COMPLETED Results posted

Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC

Details

Lead sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Phase	PHASE3
Status	COMPLETED
Enrolment	357
Start date	Fri Sep 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Squamous NSCLC

Interventions

• Sintilimab
• Gemcitabine
• Cisplatin
• Placebo
• Carboplatin

Countries

China